A novel NF-κB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors

Research in Veterinary Science

Volumn 89, Issue 3, 2010, Pages 378-382

  Matsuda, A ^a   Tanaka, A ^a   Muto, S ^b   Ohmori, K ^a   Furusaka, T ^c   Jung, K ^a   Karasawa, K ^a   Okamoto, N ^a   Oida, K ^a   Itai, A ^b   Matsuda, H ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b Inst of Medicinal Molecular Design   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glucocorticoid receptor; IMD 0354; Lymphoma leukemia; NF B

Indexed keywords

DESOXIMETASONE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; I KAPPA B; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOG; DOWN REGULATION; DRUG POTENTIATION; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION REGULATION; HORMONE RESISTANCE; HORMONE SENSITIVITY; LYMPHOID CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

ANIMALS; BENZAMIDES; BLOTTING, WESTERN; DEXAMETHASONE; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; LYMPHOCYTES; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; NF-KAPPA B; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

CANIS FAMILIARIS;

EID: 77958613310     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2010.03.017     Document Type: Article

References (22)

1. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 2001, 107:241-246.
2. Costlow M.E., Pui C.H., Dahl G.V. Glucocorticoid receptors in childhood acute lymphocytic leukemia. Cancer Res. 1982, 42:4801-4806.
3. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor-κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001, 194:1861-1874.
4. Distelhorst C.W. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002, 9:6-19.
5. Ghosh S., May M.J., Kopp E.B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998, 16:225-260.
6. Goecke I.A., Alvarez C., Henríquez J., Salas K., Molina M.L., Ferreira A., Gatica H. Methotrexate regulates the expression of glucocorticoid receptor alpha and beta isoforms in normal human peripheral mononuclear cells and human lymphocyte cell lines in vitro. Mol. Immunol. 2007, 44:2115-2123.
7. Greenstein S., Ghias K., Krett N.L., Rosen S.T. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin. Cancer Res. 2002, 8:1681-1694.
8. Joyce D., Albanese C., Steer J., Fu M., Bouzahzah B., Pestell R.G. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001, 12:73-90.
9. Kaspers G.J., Pieters R., Klumper E., DeWaal F.C., Veerman A.J. Glucocorticoid resistance in childhood leukemia. Leuk. Lymphoma 1994, 13:187-201.
10. Keller S.A., Schattner E.J., Cesarman E. Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000, 96:2537-2542.
11. Khanna C., Lindblad-Toh K., Vail D., London C., Bergman P. The dog as a cancer model. Nat. Biotechnol. 2006, 24:1065-1066.
12. Mastrangelo R., Malandrino R., Riccardi R., Longo P., Ranelletti F.O., Iacobelli S. Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia. Blood 1980, 56:1036-1040.
13. Moalli P.A., Rosen S.T. Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk. Lymphoma 1994, 15:363-374.
14. Momoi Y., Okai Y., Watari T., Goitsuka R., Tsujimoto H., Hasegawa A. Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Vet. Immunol. Immunopathol. 1997, 59:11-20.
15. Mori N., Yamada Y., Ikeda S., Yamasaki Y., Tsukasaki K., Tanaka Y., Tomonaga M., Yamamoto N., Fujii M. Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002, 100:1828-1834.
16. Nakaichi M., Taura Y., Kanki M., Mamba K., Momoi Y., Tsujimoto H., Nakama S. Establishment and characterization of a new canine B-cell leukemia cell line. J. Vet. Med. Sci. 1996, 58:469-471.
17. Neumann M., Naumann M. Beyond IκBs: alternative regulation of NF-κB activity. FASEB J. 2007, 21:2642-2654.
18. Oerlemans R., Vink J., Dijkmans B.A., Assaraf Y.G., van Miltenburg M., van der Heijden J., Ifergan I., Lems W.F., Scheper R.J., Kaspers G.J., Cloos J., Jansen G. Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis. Ann. Rheum. Dis. 2007, 66:1289-1295.
19. Tanaka A., Konno M., Muto S., Kambe N., Morii E., Nakahata T., Itai A., Matsuda H. A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005, 105:2324-2331.
20. Tanaka A., Muto S., Konno M., Itai A., Matsuda H. A new IκB inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006, 66:419-426.
21. Vail D.M., Young K.M. Hematopoietic tumors. Small Animal Clinical Oncology 2007, 699-784. W.B. Saunders, Philadelphia, USA. fourth ed. S.J. Withrow, D.M. Vail (Eds.).
22. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 2001, 107:135-142.